The Conversation (0)
GlaxoSmithKline’s HIV drug Tivicay Approved by the U.S. FDA
Aug. 13, 2013 09:43AM PST
Company News
GlaxoSmithKline Plc. (NYSE:GSK) drug Tivicay was approved by the U.S. Food and Drug Administration on Monday. Tivicay is owned by ViiV Healthcare, an HIV joint venture between GSK,Pfizer Inc and Shionogi & Co Ltd.
GlaxoSmithKline Plc. (NYSE:GSK) drug Tivicay was approved by the U.S. Food and Drug Administration on Monday. Tivicay is owned by ViiV Healthcare, an HIV joint venture between GSK,Pfizer Inc and Shionogi & Co Ltd.
As quoted in the press release:
Tivicay can be used to treat infected adults who have been treated with other drugs or are new to treatment.
The FDA also approved the drug for use in children aged 12 years and over, who weigh at least 40 kg (88 lbs) and who have not received treatment with a drug that has the same mechanism of action.
Click here to read the GlaxoSmithKline Plc. (NYSE:GSK) press release